Title
Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study
Date Issued
01 December 2021
Access level
open access
Resource Type
journal article
Author(s)
Ceccato A.
Russo A.
Barbeta E.
Oscanoa P.
Tiseo G.
Gabarrus A.
Di Giannatale P.
Nogas S.
Menichetti F.
Ferrer M.
Niederman M.
Falcone M.
Torres A.
University of Barcelona (UB)
Publisher(s)
BioMed Central Ltd
Abstract
Background: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide despite correct antibiotic use. Corticosteroids have long been evaluated as a treatment option, but heterogeneous effects on survival have precluded their widespread implementation. We aimed to evaluate whether corticosteroids might improve clinical outcomes in patients with severe CAP and high inflammatory responses. Study design and methods: We analyzed two prospective observational cohorts of patients with CAP in Barcelona and Rome who were admitted to intensive care with a high inflammatory response. Propensity score (PS) matching was used to obtain balance among the baseline variables in both groups, and we excluded patients with viral pneumonia or who received hydrocortisone. Results: Of the 610 patients admitted with severe CAP, 198 (32%) received corticosteroids and 387 had major criteria for severe CAP. All patients had a baseline serum C-reactive protein above 15 mg/dL. Patients who received corticosteroids were more commonly male, had more comorbidities (e.g., cancer or chronic obstructive pulmonary disease), and presented with significantly higher sequential organ failure assessment scores. Eighty-nine patients met major severity criteria (invasive mechanical ventilation and/or septic shock) and were matched per group. Twenty-eight-day mortality was lower among patients receiving corticosteroids (16 patients, 18%) than among those not receiving them (28 patients, 31%; p = 0.037). After PS matching, corticosteroid therapy reduced the 28-day mortality risk in patients who met major severity criteria (hazard ratio (HR) 0.53, 95% confidence interval (CI) 0.29–0.98) (p = 0.043). In patients who did not meet major severity criteria, no benefits were observed with corticosteroid use (HR 0.88 (95%CI 0.32–2.36). Conclusions: Corticosteroid treatment may be of benefit for patients with CAP who have septic shock and/or a high inflammatory response and requirement for invasive mechanical ventilation. Corticosteroids appear to have no impact on mortality when these features are not present.
Volume
25
Issue
1
Language
English
OCDE Knowledge area
Epidemiología Enfermedades infecciosas
Scopus EID
2-s2.0-85121422297
PubMed ID
Source
Critical Care
ISSN of the container
13648535
Sponsor(s)
We are indebted to all our medical and nursing colleagues for their assistance and cooperation in this study. We thank Elisabeth Sancho for her administrative support. We thank Michael Maudsley (University of Barcelona) for his assistance in reviewing the language of the manuscript. This study was supported by CIBERES and IDIBAPS. The funding sources had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Sources of information: Directorio de Producción Científica Scopus